Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common-Size Income Statement

Paying user area

Try for free

Biogen Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Biogen Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenue
Cost of sales, excluding amortization and impairment of acquired intangible assets
Gross profit
Research and development
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration profit sharing
Gain (loss) on divestiture of Hillerød, Denmark manufacturing operations
Gain (loss) on fair value remeasurement of contingent consideration
Acquired in-process research and development
Restructuring charges
Income from operations
Interest income
Interest expense
Gain (loss) on investments, net
Foreign exchange gains (losses), net
Other, net
Other income (expense), net
Income before equity in income (loss) of investee and income tax expense
Equity in income (loss) of investee, net of tax
Income before income tax expense
Income tax expense
Net income
Net income attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc. income from operations as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.
Income before income tax expense Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc. income before income tax expense as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc. net income attributable to Biogen Inc. as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.